Compare Stocks

Date Range: 

 Mersana TherapeuticsNkartaY-mAbs TherapeuticsPhathom PharmaceuticalsOmeros
SymbolNASDAQ:MRSNNASDAQ:NKTXNASDAQ:YMABNASDAQ:PHATNASDAQ:OMER
Price Information
Current Price$14.91$25.92$28.65$33.65$17.56
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.21.71.61.81.4
Analysis Score3.43.53.43.33.3
Community Score2.73.52.52.53.0
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.72.50.8
Earnings & Valuation Score0.00.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$26.17$59.00$55.43$53.00$23.00
% Upside from Price Target75.50% upside127.62% upside93.47% upside57.50% upside30.98% upside
Trade Information
Market Cap$1.04 billion$899.68 million$1.23 billion$1.10 billion$1.11 billion
Beta2.54N/A1.361.321.65
Average Volume951,708233,946296,491101,809701,211
Sales & Book Value
Annual Revenue$42.12 millionN/AN/AN/A$111.81 million
Price / Sales24.44N/AN/AN/A9.79
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.64 per shareN/A$5.01 per share$9.29 per share($2.19) per share
Price / Book9.09N/AN/AN/A-8.02
Profitability
Net Income$-28,210,000.00N/A$-81,030,000.00$-255,130,000.00$-84,490,000.00
EPS($0.65)N/A($2.30)($13.98)($0.96)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-8,772.91%N/AN/AN/A-134.59%
Return on Equity (ROE)-45.16%N/A-74.98%-88.73%N/A
Return on Assets (ROA)-37.53%N/A-66.70%-69.04%-59.49%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.02%N/AN/A0.26%N/A
Current Ratio13.05%34.88%10.40%8.21%4.11%
Quick Ratio13.05%34.88%10.40%8.21%4.07%
Ownership Information
Institutional Ownership PercentageN/A77.12%53.20%73.80%56.63%
Insider Ownership Percentage5.30%N/A38.40%39.80%11.30%
Miscellaneous
Employees1109512525277
Shares Outstanding69.05 million32.87 million43.56 million31.32 million62.33 million
Next Earnings Date5/10/2021 (Confirmed)6/24/2021 (Estimated)5/6/2021 (Confirmed)5/11/2021 (Estimated)5/10/2021 (Confirmed)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Omeros (OMER) to Release Earnings on MondayOmeros (OMER) to Release Earnings on Monday
americanbankingnews.com - May 6 at 1:30 PM
Omeros Co. (NASDAQ:OMER) Expected to Post FY2022 Earnings of ($1.26) Per ShareOmeros Co. (NASDAQ:OMER) Expected to Post FY2022 Earnings of ($1.26) Per Share
americanbankingnews.com - May 6 at 11:12 AM
Over The Wire completes carrier interconnect program - Telco - CRN AustraliaOver The Wire completes carrier interconnect program - Telco - CRN Australia
crn.com.au - May 5 at 6:12 PM
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021 - Galveston County Daily NewsOmeros Corporation to Announce First Quarter Financial Results on May 10, 2021 - Galveston County Daily News
galvnews.com - May 5 at 1:12 PM
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
finance.yahoo.com - May 5 at 1:12 PM
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration - Business WireOmeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration - Business Wire
businesswire.com - May 5 at 8:12 AM
Omeros (NASDAQ:OMER) Upgraded at Zacks Investment ResearchOmeros (NASDAQ:OMER) Upgraded at Zacks Investment Research
marketbeat.com - May 5 at 5:11 AM
CDC and CMS OKs Omeros ICD-10 codes for HSCT-TMA diagnosis and narsoplimab - Seeking AlphaCDC and CMS OKs Omeros' ICD-10 codes for HSCT-TMA diagnosis and narsoplimab - Seeking Alpha
seekingalpha.com - May 4 at 8:04 PM
Omeros (NASDAQ:OMER) Shareholders Have Enjoyed A 42% Share Price Gain - Yahoo FinanceOmeros (NASDAQ:OMER) Shareholders Have Enjoyed A 42% Share Price Gain - Yahoo Finance
finance.yahoo.com - May 4 at 3:04 PM
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration - Yahoo FinanceOmeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration - Yahoo Finance
finance.yahoo.com - May 4 at 10:03 AM
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab AdministrationOmeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
finance.yahoo.com - May 4 at 10:03 AM
Memory Impairment Treatment Market Estimated To Experience A Hike In Growth By 2026| F. Hoffmann-La Roche Ltd., Suven Life Sciences Ltd., Met P Pharma AG, Dart NeuroScience LLC., Omeros Corporation, Sunovion Pharmaceuticals Inc. - Clark County BlogMemory Impairment Treatment Market Estimated To Experience A Hike In Growth By 2026| F. Hoffmann-La Roche Ltd., Suven Life Sciences Ltd., Met P Pharma AG, Dart NeuroScience LLC., Omeros Corporation, Sunovion Pharmaceuticals Inc. - Clark County Blog
clarkcountyblog.com - May 3 at 1:45 PM
Omeros (NASDAQ:OMER) Price Target Cut to $32.00 by Analysts at HC WainwrightOmeros (NASDAQ:OMER) Price Target Cut to $32.00 by Analysts at HC Wainwright
americanbankingnews.com - May 3 at 8:34 AM
Omeros (NASDAQ:OMER) PT Lowered to $32.00 at HC WainwrightOmeros (NASDAQ:OMER) PT Lowered to $32.00 at HC Wainwright
americanbankingnews.com - May 3 at 8:34 AM
 Analysts Anticipate Omeros Co. (NASDAQ:OMER) Will Post Earnings of -$0.51 Per Share Analysts Anticipate Omeros Co. (NASDAQ:OMER) Will Post Earnings of -$0.51 Per Share
americanbankingnews.com - May 2 at 6:14 PM
Obsessive-Compulsive Disorder Treatment Market to Witness Huge Growth by 2027 | C4X Discovery Limited, Omeros Corporation, Sellas Inc. and Others – Clark County Blog - Clark County BlogObsessive-Compulsive Disorder Treatment Market to Witness Huge Growth by 2027 | C4X Discovery Limited, Omeros Corporation, Sellas Inc. and Others – Clark County Blog - Clark County Blog
clarkcountyblog.com - April 30 at 2:15 PM
How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own? - NasdaqHow Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own? - Nasdaq
nasdaq.com - April 29 at 10:43 PM
Massive Growth of Plasminogen Market by 2026 | Kedrion, Prometic, Genentech (Roche), Boehringer Ingelheim, Kyowa Hakko Kirin, Omeros Corporation - Clark County BlogMassive Growth of Plasminogen Market by 2026 | Kedrion, Prometic, Genentech (Roche), Boehringer Ingelheim, Kyowa Hakko Kirin, Omeros Corporation - Clark County Blog
clarkcountyblog.com - April 29 at 7:42 AM
Omeros narsoplimab to replace Alexions Soliris in HSCT-TMA - Clinical Trials ArenaOmeros' narsoplimab to replace Alexion's Soliris in HSCT-TMA - Clinical Trials Arena
clinicaltrialsarena.com - April 29 at 7:42 AM
Global Eating Disorder Market Leading Players, Share, Demand, Future Growth, Business Prospects 2027||INSYS THERAPEUTICS, INC, Omeros Corporation, KUHNIL, Sunovion Pharmaceuticals, Inc., Alkermes – Valley Bugler Newspaper - Valley Bugler NewspaperGlobal Eating Disorder Market Leading Players, Share, Demand, Future Growth, Business Prospects 2027||INSYS THERAPEUTICS, INC, Omeros Corporation, KUHNIL, Sunovion Pharmaceuticals, Inc., Alkermes – Valley Bugler Newspaper - Valley Bugler Newspaper
valleybugler.com - April 28 at 1:02 PM
World Atypical Hemolytic Uremic Syndrome Drug Market 2020: Industry Size, Demand, Dynamics, Business Growth and 2026 Forecasts (Achillion Pharmaceuticals Inc, Omeros Corp, Amgen Inc, Akari Therapeutics Plc, More) - Clark County BlogWorld Atypical Hemolytic Uremic Syndrome Drug Market 2020: Industry Size, Demand, Dynamics, Business Growth and 2026 Forecasts (Achillion Pharmaceuticals Inc, Omeros Corp, Amgen Inc, Akari Therapeutics Plc, More) - Clark County Blog
clarkcountyblog.com - April 27 at 8:10 PM
Is Omeros Corporation (OMER) a Stock to Watch After Losing -3.50% This Week? - InvestorsObserverIs Omeros Corporation (OMER) a Stock to Watch After Losing -3.50% This Week? - InvestorsObserver
investorsobserver.com - April 27 at 8:10 PM
PDE Inhibitors Market Estimated To Experience A Hike In Growth By 2026| Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, Pfizer, Omeros, Anacor Pharmaceuticals, Otsuka - Clark County BlogPDE Inhibitors Market Estimated To Experience A Hike In Growth By 2026| Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, Pfizer, Omeros, Anacor Pharmaceuticals, Otsuka - Clark County Blog
clarkcountyblog.com - April 27 at 10:09 AM
After Surging 1.52% During Past Week, Is Omeros Corporation (NASDAQ:OMER) Still A Buy?After Surging 1.52% During Past Week, Is Omeros Corporation (NASDAQ:OMER) Still A Buy?
marketingsentinel.com - April 26 at 8:21 AM
Omeros (NASDAQ:OMER) Given New $32.00 Price Target at HC WainwrightOmeros (NASDAQ:OMER) Given New $32.00 Price Target at HC Wainwright
marketbeat.com - April 26 at 7:41 AM
New Research: Plasminogen Market 2026 Industry Specifications and Outlook 2021| Genentech (Roche), Boehringer Ingelheim, Kyowa Hakko Kirin, Omeros Corporation, – Clark County Blog - Clark County BlogNew Research: Plasminogen Market 2026 Industry Specifications and Outlook 2021| Genentech (Roche), Boehringer Ingelheim, Kyowa Hakko Kirin, Omeros Corporation, – Clark County Blog - Clark County Blog
clarkcountyblog.com - April 23 at 2:18 PM
Trending News:: PDE Inhibitors Market Segmentation and Development Forecast till 2026| | Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, Pfizer, Omeros - Clark County BlogTrending News:: PDE Inhibitors Market Segmentation and Development Forecast till 2026| | Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, Pfizer, Omeros - Clark County Blog
clarkcountyblog.com - April 23 at 9:17 AM
DateCompanyBrokerageAction
3/30/2021Mersana TherapeuticsCredit Suisse GroupInitiated Coverage
12/2/2020Mersana TherapeuticsStifel NicolausInitiated Coverage
11/9/2020Mersana TherapeuticsSVB LeerinkBoost Price Target
9/29/2020Mersana TherapeuticsJPMorgan Chase & Co.Initiated Coverage
6/24/2020Mersana TherapeuticsBTIG ResearchBoost Price Target
6/23/2020Mersana TherapeuticsHC WainwrightReiterated Rating
5/28/2020Mersana TherapeuticsRobert W. BairdBoost Price Target
1/13/2020Mersana TherapeuticsCowenReiterated Rating
9/18/2018Mersana TherapeuticsWedbushBoost Price Target
3/17/2021NkartaCantor FitzgeraldReiterated Rating
12/23/2020NkartaMizuhoBoost Price Target
8/4/2020NkartaEvercore ISIInitiated Coverage
1/15/2021Y-mAbs TherapeuticsBank of AmericaDowngrade
12/17/2020Y-mAbs TherapeuticsBarclaysBoost Price Target
11/12/2020Y-mAbs TherapeuticsMorgan StanleyBoost Price Target
10/19/2020Y-mAbs TherapeuticsCanaccord GenuityReiterated Rating
5/1/2020Y-mAbs TherapeuticsJanney Montgomery ScottInitiated Coverage
2/17/2021Phathom PharmaceuticalsBMO Capital MarketsInitiated Coverage
2/2/2021Phathom PharmaceuticalsGuggenheimInitiated Coverage
1/28/2021Phathom PharmaceuticalsJonestradingInitiated Coverage
12/15/2020Phathom PharmaceuticalsNeedham & Company LLCBoost Price Target
6/26/2020Phathom PharmaceuticalsThe Goldman Sachs GroupDowngrade
11/27/2019Phathom PharmaceuticalsJefferies Financial GroupInitiated Coverage
2/1/2021OmerosUBS GroupInitiated Coverage
12/4/2020OmerosMaxim GroupBoost Price Target
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.